BiotechTube

rituximab (Mabthera®) + Placebo

Phase 3Completed
2 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Warm Autoimmune Hemolytic Anemia

Conditions

Warm Autoimmune Hemolytic Anemia

Trial Timeline

Mar 3, 2011 → Jan 8, 2016

NCT ID
NCT01181154

About rituximab (Mabthera®) + Placebo

rituximab (Mabthera®) + Placebo is a phase 3 stage product being developed by Roche for Warm Autoimmune Hemolytic Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01181154. Target conditions include Warm Autoimmune Hemolytic Anemia.

What happened to similar drugs?

0 of 5 similar drugs in Warm Autoimmune Hemolytic Anemia were approved

Approved (0) Terminated (1) Active (4)
🔄Ianalumab + PlaceboNovartisPhase 3
❌parsaclisinib + placeboIncytePhase 3
🔄Obexelimab + ObexelimabZenas BioPharmaPhase 3
🔄Fostamatinib disodiumRigel PharmaceuticalsPhase 3
🔄Fostamatinib disodium + PlaceboRigel PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01181154Phase 3Completed

Competing Products

12 competing products in Warm Autoimmune Hemolytic Anemia

See all competitors
ProductCompanyStageHype Score
Ianalumab + PlaceboNovartisPhase 3
44
rilzabrutinibSanofiPhase 2
39
Isatuximab SAR650984SanofiPhase 2
27
parsaclisinib + placeboIncytePhase 3
29
RVT-1401 680 mg/weekly + RVT-1401 340 mg/weeklyImmunovantPhase 2
24
HMPL-523(300mg PO QD) + PlaceboHUTCHMEDPhase 2/3
36
APL-2Apellis PharmaceuticalsPhase 2
29
Obexelimab + ObexelimabZenas BioPharmaPhase 3
38
ANX005AnnexonPhase 2
29
Fostamatinib 150 mg bidRigel PharmaceuticalsPhase 2
29
Fostamatinib disodiumRigel PharmaceuticalsPhase 3
41
Fostamatinib disodium + PlaceboRigel PharmaceuticalsPhase 3
34